Back to Agmatine Sulfate

Timing & pharmacokinetics

How long does Agmatine Sulfate take to work?

Onset timing for Agmatine Sulfate varies in the clinical literature. Onset timing is not well-quantified in our dataset, refer to clinical citations on the main entry.

Onset

Half-life

2h

Duration

Timing

with meals

Key facts

typical dose
500–2500 mg
dose frequency
1-3 doses
timing
with meals
with food
with meal
half-life
2 hours
safety score
4/5
evidence grade
B
class
amino-acid
PubMed citations
600
legal status (US)
Over-the-counter
legal status (UK)
Over-the-counter
legal status (EU)
Over-the-counter
legal status (AU)
Over-the-counter
primary mechanism
Low-affinity NMDA receptor antagonist (similar mechanism to memantine), modulates nitric oxide synthase, and binds imidazoline receptors.

Onset window

Agmatine Sulfate onset times in the published literature vary widely. Refer to the citations on the main Agmatine Sulfate entry for compound-specific pharmacokinetic data.

Food effect: Taking with food slows absorption but improves tolerance. Onset shifts 30–60 minutes later than empty-stomach dosing.

Half-life and dosing frequency

Short 2-hour half-life, most of the dose is cleared by mid-afternoon if taken in the morning.

Acute vs. chronic effect

Some nootropics work the first time you take them (Agmatine Sulfate may or may not). Others, adaptogens, racetams, and most botanicals targeting BDNF or NGF pathways, require 2–4 weeks of daily dosing before the full effect emerges.

If you don’t feel anything after a single dose and the compound is in the chronic-effect category, that is normal, extend the trial to 2–4 weeks before evaluating. If it is in the acute category and you feel nothing, consider dose, vendor sourcing, or whether the compound matches your goal.

Mechanism, safety, and citations for Agmatine Sulfate are on the main reference page, see Agmatine Sulfate. For full dose protocol see Agmatine Sulfate dosage. To check for stack-level pharmacokinetic conflicts, use the interaction checker.

Onset and pharmacokinetic data reflect the published literature for healthy adults at typical doses. Individual variation in absorption, metabolism (CYP genotype), and gut transit can shift onset by ±50%. This page is informational and not medical advice. See our full disclaimer.